Summer Street reckons that approval for Sarepta's (SRPT +2.7%) Eteplirsen drug for treating...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Summer Street reckons that approval for Sarepta's (SRPT +2.7%) Eteplirsen drug for treating Duchenne muscular dystrophy could be years away as it is not yet ready for FDA review. A "recent trial of 12 patients is not even close to what is needed," a consultant says. One reaction on Twitter is that "Summer Street has a lot of upset clients stuck short $SRPT...this is a lame attempt to disseminate and destroy."